Compare CIG & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | CIG | GPCR |
|---|---|---|
| Founded | 1952 | 2016 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.3B |
| IPO Year | N/A | 2023 |
| Metric | CIG | GPCR |
|---|---|---|
| Price | $2.16 | $82.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $103.09 |
| AVG Volume (30 Days) | ★ 4.5M | 1.2M |
| Earning Date | 03-20-2026 | 02-26-2026 |
| Dividend Yield | ★ 11.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $7,960,960,695.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.44 | ★ N/A |
| Revenue Growth | ★ 9.92 | N/A |
| 52 Week Low | $1.59 | $13.22 |
| 52 Week High | $2.30 | $94.90 |
| Indicator | CIG | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 56.27 | 54.31 |
| Support Level | $1.96 | $86.10 |
| Resistance Level | $2.25 | $92.06 |
| Average True Range (ATR) | 0.06 | 4.80 |
| MACD | 0.01 | -1.62 |
| Stochastic Oscillator | 69.20 | 19.77 |
Cia Energetica DE Minas Gerais - Cemig, formerly Energy Company of Minas Gerais, is a Brazilian power company that generates, transmits, and distributes electricity. As one of the power companies in Brazil, the firm operates across Brazilian states and Chile. The company has various subsidiaries and operates chiefly through its generation, transmission, distribution, and gas segments. The majority of the company's revenue is derived from electricity sales to consumers. The company generates power through hydroelectric resources and, secondarily, through thermal and wind resources.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.